Plerixafor, a Food and Drug Administration-approved CXCR4 antagonist for hematopoietic stem cell mobilization, is effective at mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma when administered with G-CSF. 1 Most centers initiate peripheral blood hematopoietic stem cell apheresis early in the week, as some patients require 4 to 5 days to achieve satisfactory stem cell yields. The regimen of filgrastim and plerixafor requires filgrastim administration daily, starting 4 days before apheresis, and plerixafor administration at 2100 hours on the day before apheresis, each to continue throughout the apheresis period. 1 This administration scheme creates practical barriers for patients, physicians, and support staff. The primary barriers include administration of filgrastim over a weekend and plerixafor in the late evening. The alternate timing of plerixafor dosing appears to be effective in the initial reports.
2 Pegylated filgrastim has shown efficacy and safety in mobilizing peripheral blood hematopoietic stem cells in healthy donors and patients with multiple myeloma. 3 We are unaware of reports using a combination of pegylated filgrastim, filgrastim, and plerixafor for hematopoietic stem cell mobilization and would like to describe our experience with a patient receiving this regimen.
A 46-year-old Caucasian woman was diagnosed with grade 2 stage I follicular lymphoma 9 years ago by the core biopsy of a submental lymph node. The patient received external beam radiotherapy to the lymph node and was disease-free for 2 years, when a [ progressed after the initial partial response on PET/CT scan 1 year later. An attempt at stem cell mobilization with a combination of GM-CSF and G-CSF was aborted because of hypotension with altered mental status. It was believed that a recent increase in benzodiazepine intake by the patient, and not the GM or G-CSF, was responsible for the symptoms. A second mobilization was planned 6 months later. Owing to transportation difficulties and change in social support, the patient could not receive G-CSF over the weekend. Because of the efficacy of plerixafor, we decided to use this as part of the mobilization regimen. We obtained patient consent for off-label combination use of pegylated filgrastim and plerixafor. (See Figure 1 for a graphical display of the mobilization and apheresis course.) The patient's mobilization regimen consisted of the following: 6 mg pegylated filgrastim administered s.c. once on day 1; 10 mcg/kg filgrastim administered s.c. daily, starting on day 4 through the end of apheresis; 240 mcg/kg plerixafor administered s.c. daily, and at 1700 hours on day 4. Fifteen-liter, four-hour daily apheresis sessions were initiated on Tuesday day four at 0800 hours. The peripheral blood CD34 count by flow cytometry on day 5 before apheresis was 30 cells/mcl, and 2.62 Â 10 6 cells/kg were collected. A total of 6.02 Â 10 6 CD34 cells/kg were collected in three apheresis sessions. The patient received BEAC conditioning before autologous hematopoietic transplant. Neutrophil engraftment was done on day þ 10, with pegylated filgrastim being administered on day þ 5. The patient was recently discharged (on day þ 12) and is doing well. This report suggests that safe and effective mobilization can be achieved in a patient with prior radiotherapy and radioimmunotherapy for non-Hodgkin's lymphoma with the combination of pegylated filgrastim, filgrastim and plerixafor. We have no reason to believe that use of a pegylated form of filgrastim would affect the mobilization efficacy or toxicity with plerixafor. We are not certain of the necessity of filgrastim when using pegylated filgrastim with plerixafor mobilization, but the administration schedule we used spared the inconvenience of weekend filgrastim and daily 2100 plerixafor administration. Hopefully, our case will serve as a stimulus for larger centers to study safe and practical mobilization regimens such as the one above, which will allow enhanced convenience for patients.
